Location of pathogenic variants in <i>PSEN1</i> impacts progression of cognitive, clinical, and neurodegenerative measures in autosomal‐dominant Alzheimer's disease

Schultz, Stephanie A. Shirzadi, Zahra Schultz, Aaron P. Liu, Lei Fitzpatrick, Colleen D. McDade, Eric Barthelemy, Nicolas R. Renton, Alan Esposito, Bianca Joseph‐Mathurin, Nelly Cruchaga, Carlos Chen, Charles D. Goate, Alison Allegri, Ricardo Francisco Benzinger, Tammie L. S. Berman, Sarah Chui, Helena C. Fagan, Anne M. Farlow, Martin R. Fox, Nick C. Gordon, Brian A. Day, Gregory S. Graff‐Radford, Neill R. Hassenstab, Jason J. Hanseeuw, Bernard [UCL] Hofmann, Anna Jack, Clifford R. Jucker, Mathias Karch, Celeste M. Koeppe, Robert A. Lee, Jae‐Hong Levey, Allan I. Levin, Johannes Martins, Ralph N. Mori, Hiroshi Morris, John C. Noble, James Perrin, Richard J. Rosa‐Neto, Pedro Salloway, Stephen P. Sanchez‐Valle, Raquel Schofield, Peter R. Xiong, Chengjie Johnson, Keith A. Bateman, Randall J. Sperling, Reisa A. Chhatwal, Jasmeer P. et al.[show all]

Although pathogenic variants in PSEN1 leading to autosomal-dominant Alzheimer disease (ADAD) are highly penetrant, substantial interindividual variability in the rates of cognitive decline and biomarker change are observed in ADAD. We hypothesized that this interindividual variability may be associated with the location of the pathogenic variant within PSEN1. PSEN1 pathogenic variant carriers participating in the Dominantly Inherited Alzheimer Network (DIAN) observational study were grouped based on whether the underlying variant affects a transmembrane (TM) or cytoplasmic (CY) protein domain within PSEN1. CY and TM carriers and variant non-carriers (NC) who completed clinical evaluation, multimodal neuroimaging, and lumbar puncture for collection of cerebrospinal fluid (CSF) as part of their participation in DIAN were included in this study. Linear mixed effects models were used to determine differences in clinical, cognitive, and biomarker measures between the NC, TM, and CY groups. While both the CY and TM groups were found to have similarly elevated Aβ compared to NC, TM carriers had greater cognitive impairment, smaller hippocampal volume, and elevated phosphorylated tau levels across the spectrum of pre-symptomatic and symptomatic phases of disease as compared to CY, using both cross-sectional and longitudinal data. As distinct portions of PSEN1 are differentially involved in APP processing by γ-secretase and the generation of toxic β-amyloid species, these results have important implications for understanding the pathobiology of ADAD and accounting for a substantial portion of the interindividual heterogeneity in ongoing ADAD clinical trials.